http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 05 Jun 2026 06:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Jun+04/26607940.html si-local-file:///var/storage/secattach/20260605/26607940.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Jun+04/26607940.html Fri, 05 Jun 2026 06:02:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Jun+04/26607940.html si-local-file:///var/storage/secattach/20260605/26607940.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Jun+04/26607940.html Fri, 05 Jun 2026 06:02:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Jun+04/26607940.html si-local-file:///var/storage/secattach/20260605/26607940.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Jun+04/26607940.html Fri, 05 Jun 2026 06:02:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/Press+Releases/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html <div class="xn-content"> <p><i>Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from <chron>March 24, 2025</chron> through <chron>March 12, 2026</chron> may wish to evaluate lead plaintiff opportunities in a pending securities class action. <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4698020-6&amp;h=4221010898&amp;u=https%3A%2F%2Fsuewallst.com%2Fcases%2Fimmutep-limited-lawsuit-submission-form%3Fprid%3D186206%26wire%3D4&amp;a=Request+an+institutional+investor+loss+assessment" target="_blank" rel="nofollow">Request an institutional investor loss assessment</a>. You may also contact <person>Joseph E. Levi</person>, Esq. at <a target="_blank" href="mailto:jlevi@SueWallSt.com" target="_blank" rel="nofollow">jlevi@SueWallSt.com</a> or (888) SueWallSt.</p> http://www.streetinsider.com/Press+Releases/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html Thu, 28 May 2026 09:00:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/Press+Releases/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html <div class="xn-content"> <p><i>Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from <chron>March 24, 2025</chron> through <chron>March 12, 2026</chron> may wish to evaluate lead plaintiff opportunities in a pending securities class action. <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4698020-6&amp;h=4221010898&amp;u=https%3A%2F%2Fsuewallst.com%2Fcases%2Fimmutep-limited-lawsuit-submission-form%3Fprid%3D186206%26wire%3D4&amp;a=Request+an+institutional+investor+loss+assessment" target="_blank" rel="nofollow">Request an institutional investor loss assessment</a>. You may also contact <person>Joseph E. Levi</person>, Esq. at <a target="_blank" href="mailto:jlevi@SueWallSt.com" target="_blank" rel="nofollow">jlevi@SueWallSt.com</a> or (888) SueWallSt.</p> http://www.streetinsider.com/Press+Releases/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html Thu, 28 May 2026 09:00:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/Press+Releases/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html <div class="xn-content"> <p><i>Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from <chron>March 24, 2025</chron> through <chron>March 12, 2026</chron> may wish to evaluate lead plaintiff opportunities in a pending securities class action. <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4698020-6&amp;h=4221010898&amp;u=https%3A%2F%2Fsuewallst.com%2Fcases%2Fimmutep-limited-lawsuit-submission-form%3Fprid%3D186206%26wire%3D4&amp;a=Request+an+institutional+investor+loss+assessment" target="_blank" rel="nofollow">Request an institutional investor loss assessment</a>. You may also contact <person>Joseph E. Levi</person>, Esq. at <a target="_blank" href="mailto:jlevi@SueWallSt.com" target="_blank" rel="nofollow">jlevi@SueWallSt.com</a> or (888) SueWallSt.</p> http://www.streetinsider.com/Press+Releases/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html Thu, 28 May 2026 09:00:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/PRNewswire/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html <div class="xn-content"> <p><i>Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from <chron>March 24, 2025</chron> through <chron>March 12, 2026</chron> may wish to evaluate lead plaintiff opportunities in a pending securities class action. <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4698020-6&amp;h=4221010898&amp;u=https%3A%2F%2Fsuewallst.com%2Fcases%2Fimmutep-limited-lawsuit-submission-form%3Fprid%3D186206%26wire%3D4&amp;a=Request+an+institutional+investor+loss+assessment" target="_blank" rel="nofollow">Request an institutional investor loss assessment</a>. You may also contact <person>Joseph E. Levi</person>, Esq. at <a target="_blank" href="mailto:jlevi@SueWallSt.com" target="_blank" rel="nofollow">jlevi@SueWallSt.com</a> or (888) SueWallSt.</p> http://www.streetinsider.com/PRNewswire/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html Thu, 28 May 2026 09:00:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/PRNewswire/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html <div class="xn-content"> <p><i>Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from <chron>March 24, 2025</chron> through <chron>March 12, 2026</chron> may wish to evaluate lead plaintiff opportunities in a pending securities class action. <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4698020-6&amp;h=4221010898&amp;u=https%3A%2F%2Fsuewallst.com%2Fcases%2Fimmutep-limited-lawsuit-submission-form%3Fprid%3D186206%26wire%3D4&amp;a=Request+an+institutional+investor+loss+assessment" target="_blank" rel="nofollow">Request an institutional investor loss assessment</a>. You may also contact <person>Joseph E. Levi</person>, Esq. at <a target="_blank" href="mailto:jlevi@SueWallSt.com" target="_blank" rel="nofollow">jlevi@SueWallSt.com</a> or (888) SueWallSt.</p> http://www.streetinsider.com/PRNewswire/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html Thu, 28 May 2026 09:00:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/PRNewswire/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html <div class="xn-content"> <p><i>Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from <chron>March 24, 2025</chron> through <chron>March 12, 2026</chron> may wish to evaluate lead plaintiff opportunities in a pending securities class action. <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4698020-6&amp;h=4221010898&amp;u=https%3A%2F%2Fsuewallst.com%2Fcases%2Fimmutep-limited-lawsuit-submission-form%3Fprid%3D186206%26wire%3D4&amp;a=Request+an+institutional+investor+loss+assessment" target="_blank" rel="nofollow">Request an institutional investor loss assessment</a>. You may also contact <person>Joseph E. Levi</person>, Esq. at <a target="_blank" href="mailto:jlevi@SueWallSt.com" target="_blank" rel="nofollow">jlevi@SueWallSt.com</a> or (888) SueWallSt.</p> http://www.streetinsider.com/PRNewswire/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html Thu, 28 May 2026 09:00:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html <ul type="disc"><li style="margin-top:8pt; margin-bottom:8pt;">Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial</li><li style="margin-top:8pt; margin-bottom:8pt;">Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review</li><li style="margin-top:8pt; margin-bottom:8pt;">Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026</li><li style="margin-top:8pt; margin-bottom:8pt;">Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.</li></ul> <p align="justify"><b><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b></b><a target="_blank" http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html Thu, 30 Apr 2026 08:00:00 -0400 A.37819586 IMM IMMP O.00000304 O.00768283 http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html <ul type="disc"><li style="margin-top:8pt; margin-bottom:8pt;">Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial</li><li style="margin-top:8pt; margin-bottom:8pt;">Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review</li><li style="margin-top:8pt; margin-bottom:8pt;">Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026</li><li style="margin-top:8pt; margin-bottom:8pt;">Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.</li></ul> <p align="justify"><b><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b></b><a target="_blank" http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html Thu, 30 Apr 2026 08:00:00 -0400 A.37819586 IMM IMMP O.00000304 O.00768283 http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html <ul type="disc"><li style="margin-top:8pt; margin-bottom:8pt;">Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial</li><li style="margin-top:8pt; margin-bottom:8pt;">Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review</li><li style="margin-top:8pt; margin-bottom:8pt;">Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026</li><li style="margin-top:8pt; margin-bottom:8pt;">Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.</li></ul> <p align="justify"><b><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b></b><a target="_blank" http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html Thu, 30 Apr 2026 08:00:00 -0400 A.37819586 IMM IMMP O.00000304 O.00768283 http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html <ul type="disc"><li style="margin-top:8pt; margin-bottom:8pt;">Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial</li><li style="margin-top:8pt; margin-bottom:8pt;">Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review</li><li style="margin-top:8pt; margin-bottom:8pt;">Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026</li><li style="margin-top:8pt; margin-bottom:8pt;">Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.</li></ul> <p align="justify"><b><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b></b><a target="_blank" http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html Thu, 30 Apr 2026 08:00:00 -0400 A.37819586 IMM IMMP O.00000304 O.00768283 http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html <ul type="disc"><li style="margin-top:8pt; margin-bottom:8pt;">Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial</li><li style="margin-top:8pt; margin-bottom:8pt;">Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review</li><li style="margin-top:8pt; margin-bottom:8pt;">Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026</li><li style="margin-top:8pt; margin-bottom:8pt;">Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.</li></ul> <p align="justify"><b><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b></b><a target="_blank" http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html Thu, 30 Apr 2026 08:00:00 -0400 A.37819586 IMM IMMP O.00000304 O.00768283 http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html <ul type="disc"><li style="margin-top:8pt; margin-bottom:8pt;">Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial</li><li style="margin-top:8pt; margin-bottom:8pt;">Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review</li><li style="margin-top:8pt; margin-bottom:8pt;">Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026</li><li style="margin-top:8pt; margin-bottom:8pt;">Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.</li></ul> <p align="justify"><b><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b></b><a target="_blank" http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html Thu, 30 Apr 2026 08:00:00 -0400 A.37819586 IMM IMMP O.00000304 O.00768283 http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html <ul type="disc"><li style="margin-top:8pt; margin-bottom:8pt;">Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial</li><li style="margin-top:8pt; margin-bottom:8pt;">Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review</li><li style="margin-top:8pt; margin-bottom:8pt;">Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026</li><li style="margin-top:8pt; margin-bottom:8pt;">Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.</li></ul> <p align="justify"><b><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b></b><a target="_blank" http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html Thu, 30 Apr 2026 08:00:00 -0400 A.37819586 IMM IMMP O.00000304 O.00768283 http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html <ul type="disc"><li style="margin-top:8pt; margin-bottom:8pt;">Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial</li><li style="margin-top:8pt; margin-bottom:8pt;">Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review</li><li style="margin-top:8pt; margin-bottom:8pt;">Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026</li><li style="margin-top:8pt; margin-bottom:8pt;">Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.</li></ul> <p align="justify"><b><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b></b><a target="_blank" http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html Thu, 30 Apr 2026 08:00:00 -0400 A.37819586 IMM IMMP O.00000304 O.00768283 http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html <ul type="disc"><li style="margin-top:8pt; margin-bottom:8pt;">Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial</li><li style="margin-top:8pt; margin-bottom:8pt;">Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review</li><li style="margin-top:8pt; margin-bottom:8pt;">Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026</li><li style="margin-top:8pt; margin-bottom:8pt;">Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.</li></ul> <p align="justify"><b><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b></b><a target="_blank" http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html Thu, 30 Apr 2026 08:00:00 -0400 A.37819586 IMM IMMP O.00000304 O.00768283 http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html <ul type="disc"><li style="margin-top:8pt; margin-bottom:8pt;">Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial</li><li style="margin-top:8pt; margin-bottom:8pt;">Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review</li><li style="margin-top:8pt; margin-bottom:8pt;">Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026</li><li style="margin-top:8pt; margin-bottom:8pt;">Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.</li></ul> <p align="justify"><b><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b></b><a target="_blank" http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html Thu, 30 Apr 2026 08:00:00 -0400 A.37819586 IMM IMMP O.00000304 O.00768283 http://www.streetinsider.com/Press+Releases/Immutep+Receives+Nasdaq+Notice+of+Bid+Price+Deficiency/26401029.html <p><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=aAyZVzUuAfZv-jVmIJYumEOuTcNn8AUBymGaSe02o7f8fYYPqMPDueOPw0kNXPK8eVhD2aLTri9Y3rX3lPbQ8yBF2Yn0d5vbOz7AlmjJ3FI=" rel="nofollow" target="_blank">Immutep Limited</a> (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the Nasdaq minimum bid price requirement.</p> <p>Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US$1.00 per share. Based on the closing bid price of the Company’s American Depositary Shares for the 30 consecutive business days ended 24 April 2026, the Company does not currently meet this requirement.</p> <p>The notification has http://www.streetinsider.com/Press+Releases/Immutep+Receives+Nasdaq+Notice+of+Bid+Price+Deficiency/26401029.html Thu, 30 Apr 2026 08:00:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/Press+Releases/Immutep+Receives+Nasdaq+Notice+of+Bid+Price+Deficiency/26401029.html <p><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=aAyZVzUuAfZv-jVmIJYumEOuTcNn8AUBymGaSe02o7f8fYYPqMPDueOPw0kNXPK8eVhD2aLTri9Y3rX3lPbQ8yBF2Yn0d5vbOz7AlmjJ3FI=" rel="nofollow" target="_blank">Immutep Limited</a> (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the Nasdaq minimum bid price requirement.</p> <p>Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US$1.00 per share. Based on the closing bid price of the Company’s American Depositary Shares for the 30 consecutive business days ended 24 April 2026, the Company does not currently meet this requirement.</p> <p>The notification has http://www.streetinsider.com/Press+Releases/Immutep+Receives+Nasdaq+Notice+of+Bid+Price+Deficiency/26401029.html Thu, 30 Apr 2026 08:00:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/Press+Releases/Immutep+Receives+Nasdaq+Notice+of+Bid+Price+Deficiency/26401029.html <p><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=aAyZVzUuAfZv-jVmIJYumEOuTcNn8AUBymGaSe02o7f8fYYPqMPDueOPw0kNXPK8eVhD2aLTri9Y3rX3lPbQ8yBF2Yn0d5vbOz7AlmjJ3FI=" rel="nofollow" target="_blank">Immutep Limited</a> (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the Nasdaq minimum bid price requirement.</p> <p>Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US$1.00 per share. Based on the closing bid price of the Company’s American Depositary Shares for the 30 consecutive business days ended 24 April 2026, the Company does not currently meet this requirement.</p> <p>The notification has http://www.streetinsider.com/Press+Releases/Immutep+Receives+Nasdaq+Notice+of+Bid+Price+Deficiency/26401029.html Thu, 30 Apr 2026 08:00:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/Globe+Newswire/Immutep+Receives+Nasdaq+Notice+of+Bid+Price+Deficiency/26401029.html <p><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=aAyZVzUuAfZv-jVmIJYumEOuTcNn8AUBymGaSe02o7f8fYYPqMPDueOPw0kNXPK8eVhD2aLTri9Y3rX3lPbQ8yBF2Yn0d5vbOz7AlmjJ3FI=" rel="nofollow" target="_blank">Immutep Limited</a> (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the Nasdaq minimum bid price requirement.</p> <p>Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US$1.00 per share. Based on the closing bid price of the Company’s American Depositary Shares for the 30 consecutive business days ended 24 April 2026, the Company does not currently meet this requirement.</p> <p>The notification has http://www.streetinsider.com/Globe+Newswire/Immutep+Receives+Nasdaq+Notice+of+Bid+Price+Deficiency/26401029.html Thu, 30 Apr 2026 08:00:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/Globe+Newswire/Immutep+Receives+Nasdaq+Notice+of+Bid+Price+Deficiency/26401029.html <p><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=aAyZVzUuAfZv-jVmIJYumEOuTcNn8AUBymGaSe02o7f8fYYPqMPDueOPw0kNXPK8eVhD2aLTri9Y3rX3lPbQ8yBF2Yn0d5vbOz7AlmjJ3FI=" rel="nofollow" target="_blank">Immutep Limited</a> (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the Nasdaq minimum bid price requirement.</p> <p>Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US$1.00 per share. Based on the closing bid price of the Company’s American Depositary Shares for the 30 consecutive business days ended 24 April 2026, the Company does not currently meet this requirement.</p> <p>The notification has http://www.streetinsider.com/Globe+Newswire/Immutep+Receives+Nasdaq+Notice+of+Bid+Price+Deficiency/26401029.html Thu, 30 Apr 2026 08:00:00 -0400 IMM IMMP O.00768283 http://www.streetinsider.com/Globe+Newswire/Immutep+Receives+Nasdaq+Notice+of+Bid+Price+Deficiency/26401029.html <p><b>SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=aAyZVzUuAfZv-jVmIJYumEOuTcNn8AUBymGaSe02o7f8fYYPqMPDueOPw0kNXPK8eVhD2aLTri9Y3rX3lPbQ8yBF2Yn0d5vbOz7AlmjJ3FI=" rel="nofollow" target="_blank">Immutep Limited</a> (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the Nasdaq minimum bid price requirement.</p> <p>Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US$1.00 per share. Based on the closing bid price of the Company’s American Depositary Shares for the 30 consecutive business days ended 24 April 2026, the Company does not currently meet this requirement.</p> <p>The notification has http://www.streetinsider.com/Globe+Newswire/Immutep+Receives+Nasdaq+Notice+of+Bid+Price+Deficiency/26401029.html Thu, 30 Apr 2026 08:00:00 -0400 IMM IMMP O.00768283